Fig. 2

RCC2 down regulation in tumor cells led to increased sensitivity to STS treatment. a & b Tumor cell lines HeLa, MDA-MB-231 and CRL5800 were transfected with 3 RCC2-specific siRNA oligos (siRNA-RCC2–1, siRNA-RCC2–2, siRNA-RCC2–3) or a control siRNA (siNC) for 24 h, 48 h, and 72 h. RCC2 protein (a) and mRNA (b) were evaluated by Western blotting and quantitative real-time RT-PCR respectively. All 3 RCC2-specific siRNAs were effective in reducing RCC2 expression (mean ± S.D. of four replicates, *P < 0.01). c Tumor cells transfected with siRNA-RCC2–1, siRNA-RCC2–2, or siNC for 24 h were treated with STS at increasing concentrations (0.05, 0.1, 0.2 and 0.4 μM for HeLa; 5, 8, 10, 20 μM for MDA-MB-231; 5, 10, 30 and 50 μM for CRL5800). Surviving cells were estimated by a CellTiter-Glo® Luminescent Cell Viability Assay. Luminescence values represent the mean ± S.D. of six wells, *P < 0.05)